Locus Acquires Protein Mechanics
Locus Pharmaceuticals said last week that it has acquired Protein Mechanics, a privately held firm based in Mountain View, Calif.
Protein Mechanics’ core technology, Imagiro, simulates protein movement and structure, and is “highly synergistic” with Locus’s own fragment-based approach to computational drug design, the Locus said.
Financial terms and other details of the acquisition were not disclosed.
Tripos Appoints New Auditor
Tripos last week said that it has appointed BDO Seidman as its independent auditor. The company will review Tripos’ financial statements beginning with the quarter ending June 30, 2004.
BDO Seidman replaces Ernst & BioInform 05-03-04] .
Compugen Revenues Continue to Fall
Compugen last week reported a decline in revenues and a higher net loss for the second quarter of 2004, as it continues to focus on its therapeutic protein pipeline.
The company’s revenues declined to $984,000, from $2.9 million in the comparable period a year ago.
Compugen posted a net loss of $3.4 million, versus a net loss of $2.4 million for the second quarter of 2003.
As of June 30, 2004, Compugen had $54.8 million in cash, cash equivalents, and long-term marketable securities — enough to last for three and a half years, the company said. The company’s short-term cash holdings were $21.1 million as of June 30.
MGED Calls for Submission of Microarray Data to Public Repositories
The Microarray Gene Expression Data Society has sent a letter to about 90 scientific journals suggesting that they require authors to submit microarray data to public repositories — specifically, ArrayExpress, the Gene Expression Omnibus, or CIBEX (Center for Information Biology Gene Expression database).
The letter follows on MGED’s successful bid in 2002 to get journals to require that microarray data follow the MIAME guidelines.
While the response to that earlier letter was “extremely positive,” MGED said it believed the journals should now take the extra step of requiring data submission. “While the adoption of these standards has greatly improved the accessibility of microarray data … obtaining and comparing datasets remains a significant challenge,” the authors wrote in the letter.
According to MGED, recent “improvements in the data-entry utilities available for [GEO, ArrayExpress, and CIBEX], as well as a growing number of commercial and academic software packages capable of writing MAGE-ML documents … have lowered the barriers for data submission to the point where we as a community must now reconsider that submission to one of these databases be a requirement.”